Introduction
Neurodegenerative disease biomarkers: Guideposts for disease prevention through early diagnosis and intervention
JOHN Q. TROJANOWSKI AND HARALD HAMPEL 491
Perspectives of worldwide translational biomarker research in neurodegenerative diseases
PIERLUIGI NICOTERA AND HARALD HAMPEL 496
Biomarkers in clinical trials for neurodegenerative diseases: Regulatory perspectives and requirements
KARL BROICH, MARCO WEIERGRÄBER AND HARALD HAMPEL 498
The role of genetics for biomarker development in neurodegeneration
LARS BERTEMA AND HARALD HAMPEL 501
Functional biomarkers for neurodegenerative disorders based on the network paradigm
BARRY HORWITZ AND JAMES B. ROWE 505
Biomarkers and evolution in Alzheimer disease
STANLEY I. RAPPORT AND PETER T. NELSON 510
Neuroimaging and the question of neurodegeneration in schizophrenia
ANDREAS MEYER-LINDENBERG 514
Ethical considerations of biomarker use in neurodegenerative diseases – A case study of Alzheimer’s disease
DAVID PRVULOVIC AND HARALD HAMPEL 517
(Contents continued on bm V)

Available online at www.sciencedirect.com

SciVerse ScienceDirect


Guest Editors
Harald Hampel and John Q. Trojanowski
Review Articles

Biomarker-based dissection of neurodegenerative diseases
BOB OLSSON, HENRIK ZETTERBERG, HARALD HAMPEL AND KAJ BLENNOW 520

Staging Alzheimer’s disease progression with multimodality neuroimaging
MICHAEL EWERS, GIOVANNI B. FRISONI, STEFAN J. TEIPEL, LEA T. GRINBERG, EDSON AMARO JR., HELMUT HEINSEN, PAUL M. THOMPSON AND HARALD HAMPEL 535

Development of Alzheimer-disease neuroimaging-biomarkers using mouse models with amyloid-precursor protein-transgene expression
STEFAN J. TEIPEL, RALPH BUCHERT, JOHANNES THOME, HARALD HAMPEL AND JENS PAHNKE 547

Functional magnetic resonance imaging as a dynamic candidate biomarker for Alzheimer’s disease
DAVID PRVULOVIC, ARUN L.W. BOKDE, FRANK FALTRACO AND HARALD HAMPEL 557

Recent developments of functional magnetic resonance imaging research for drug development in Alzheimer’s disease
HARALD HAMPEL, DAVID PRVULOVIC, STEFAN J. TEIPEL AND ARUN L.W. BOKDE 570

Biomarkers for Alzheimer’s disease therapeutic trials
HARALD HAMPEL, GORDON WILCOCK, SANDRINE ANDRIEU, PAUL AISEN, KAJ BLENNOW, K. BROICH, MARIA CARRILLO, NICK C. FOX, GIOVANNI B. FRISONI, MARIA ISAAC, SIMON LOVESTONE, AGNETA NORDBERG, DAVID PRVULOVIC, CHRISTINA SAMPAIO, PHILIP SCHELTENS, MICHAEL WEINER, BENGT WINBLAD, NICOLA COLEY, BRUNO VELLAS AND FOR THE OXFORD TASK FORCE GROUP 579

Prevention trials in Alzheimer’s disease: An EU-US task force report
BRUNO VELLAS, PAUL S. AISEN, CRISTINA SAMPAIO, MARIA CARRILLO, PHILIP SCHELTENS, BRUNO SCHERRER, GIOVANNI B. FRISONI, MICHAEL WEINER, LON SCHNEIDER, SERGE GAUTHIER, CHRISTINE C. GISCHETE, SUZANNE HENDRIX, HOWARD FELDMAN, JESSE CEDERBAUM, RONALD PETERSEN, ERIC SIEMERS, SANDRINE ANDRIEU, DAVID PRVULOVIC, JACQUES TOUCHON AND HARALD HAMPEL 594

Biomarkers of Parkinson’s disease and Dementia with Lewy bodies
CLAIRE HENCHLiffe, RICHARD DODEL AND M. FLINT BEAL 601

Imaging biomarkers in Parkinson’s disease
DAVID J. BROOKS AND NICOLA PAVESE 614

The Parkinson Progression Marker Initiative (PPMI)
THE PARKINSON PROGRESSION MARKER INITIATIVE 629

Biomarkers in frontotemporal lobar degenerations—Progress and challenges
WILLIAM T. HU, JOHN Q. TROJANOWSKI AND LESLIE M. SHAW 636

On the development of markers for pathological TDP-43 in amyotrophic lateral sclerosis with and without dementia

The ALS/PDC syndrome of Guam: Potential biomarkers for an enigmatic disorder
PATRICK L. MCGEER AND JOHN C. STEELE 663

Development of biomarkers for multiple sclerosis as a neurodegenerative disorder
ULF ZIEMANN, MATHIAS WAHL, ELKE HATTINGEN AND HAYRETTIN TUMANI 670

Development of biomarkers for multiple sclerosis as a neurodegenerative disorder
ULF ZIEMANN, MATHIAS WAHL, ELKE HATTINGEN AND HAYRETTIN TUMANI 670

Discovery and development of integrative biological markers for schizophrenia
VIOLA OERTEL-KNÖCHEL, ROBERT A. BITTNER, CHRISTIAN KNÖCHEL, DAVID PRVULOVIC AND HARALD HAMPEL 686

Biomarkers for major depression and its delineation from neurodegenerative disorders
BARBARA SCHNEIDER, DAVID PRVULOVIC, VIOLA OERTEL-KNÖCHEL, CHRISTIAN KNÖCHEL, BRITTA REINKE, MARTIN GREXA, BERNHARD WEBER AND HARALD HAMPEL 703

The future of Alzheimer’s disease: The next 10 years
HARALD HAMPEL, DAVID PRVULOVIC, STEFAN TEIPEL, FRANK JESSEN, CHRISTIAN LUCKHAUS, LUTZ FRÖLICH, MATTHIAS W. RIEPE, RICHARD DODEL, THOMAS LEYHE, LARS BERTRAM, WOLFGANG HOFFMANN AND FRANK FALTRACO 718